BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 11, 2024
See today's BioWorld
Home
» GenVec Plans Merger With Diacrin Through $40M Stock Transaction
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
GenVec Plans Merger With Diacrin Through $40M Stock Transaction
April 16, 2003
By
Brady Huggett
No Comments
Not to compare the biotechnology industry - with its blockbuster drugs and groundbreaking science - with a flea market, but there are good deals in this depressed environment if you look around. (BioWorld Today)
BioWorld